IL161116A0 - Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension - Google Patents

Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension

Info

Publication number
IL161116A0
IL161116A0 IL16111602A IL16111602A IL161116A0 IL 161116 A0 IL161116 A0 IL 161116A0 IL 16111602 A IL16111602 A IL 16111602A IL 16111602 A IL16111602 A IL 16111602A IL 161116 A0 IL161116 A0 IL 161116A0
Authority
IL
Israel
Prior art keywords
irbesartan
preparation
medicaments
prevent
pulmonary hypertension
Prior art date
Application number
IL16111602A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL161116A0 publication Critical patent/IL161116A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
IL16111602A 2001-10-26 2002-10-09 Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension IL161116A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113936A FR2831446B1 (fr) 2001-10-26 2001-10-26 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
PCT/FR2002/003439 WO2003035062A1 (fr) 2001-10-26 2002-10-09 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire

Publications (1)

Publication Number Publication Date
IL161116A0 true IL161116A0 (en) 2004-08-31

Family

ID=8868812

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16111602A IL161116A0 (en) 2001-10-26 2002-10-09 Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
IL161116A IL161116A (en) 2001-10-26 2004-03-25 Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL161116A IL161116A (en) 2001-10-26 2004-03-25 Use of irbesartan for the preparation of medicinal products that are useful for preventing or treating pulmonary arterial hypertension

Country Status (24)

Country Link
US (2) US20040242567A1 (hu)
EP (1) EP1441723B1 (hu)
JP (1) JP4542777B2 (hu)
CN (1) CN100418526C (hu)
AT (1) ATE361071T1 (hu)
AU (1) AU2002350832B2 (hu)
BR (1) BR0213479A (hu)
CA (1) CA2461625C (hu)
CY (1) CY1106746T1 (hu)
DE (1) DE60219940T2 (hu)
DK (1) DK1441723T3 (hu)
EA (1) EA007952B1 (hu)
ES (1) ES2286304T3 (hu)
FR (1) FR2831446B1 (hu)
HU (1) HUP0401633A3 (hu)
IL (2) IL161116A0 (hu)
IS (1) IS2849B (hu)
MX (1) MXPA04003910A (hu)
NO (1) NO332313B1 (hu)
NZ (1) NZ532130A (hu)
PL (1) PL209263B1 (hu)
PT (1) PT1441723E (hu)
WO (1) WO2003035062A1 (hu)
ZA (1) ZA200402696B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation
CN100367959C (zh) * 2006-08-29 2008-02-13 陈俊云 一种含有依贝沙坦的药物
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
AU2022244585A1 (en) * 2021-03-23 2023-09-21 Dimerix Bioscience Pty Ltd Treatment of inflammatory diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
PT97078B (pt) * 1990-03-20 1997-07-31 Sanofi Sa Processo para a preparacao de derivados heterociclicos n-substituidos e de composicoes farmaceuticas que os contem
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
US20020068740A1 (en) 1999-12-07 2002-06-06 Mylari Banavara L. Combination of aldose reductase inhibitors and antihypertensive agents for the treatment of diabetic complications

Also Published As

Publication number Publication date
ES2286304T3 (es) 2007-12-01
FR2831446A1 (fr) 2003-05-02
NO332313B1 (no) 2012-08-27
MXPA04003910A (es) 2004-07-23
CY1106746T1 (el) 2012-05-23
HUP0401633A2 (hu) 2004-12-28
PL209263B1 (pl) 2011-08-31
DE60219940D1 (de) 2007-06-14
ATE361071T1 (de) 2007-05-15
IS7200A (is) 2004-03-29
CA2461625A1 (en) 2003-05-01
FR2831446B1 (fr) 2004-03-05
WO2003035062A1 (fr) 2003-05-01
US20040242567A1 (en) 2004-12-02
HUP0401633A3 (en) 2009-06-29
CN1610548A (zh) 2005-04-27
EP1441723A1 (fr) 2004-08-04
IS2849B (is) 2013-09-15
EP1441723B1 (fr) 2007-05-02
AU2002350832B2 (en) 2006-11-30
NO20041732L (no) 2004-07-23
DE60219940T2 (de) 2008-01-17
NZ532130A (en) 2006-10-27
IL161116A (en) 2010-12-30
JP2005506369A (ja) 2005-03-03
DK1441723T3 (da) 2007-09-10
EA200400438A1 (ru) 2004-10-28
CA2461625C (en) 2011-07-05
CN100418526C (zh) 2008-09-17
JP4542777B2 (ja) 2010-09-15
US20090247510A1 (en) 2009-10-01
BR0213479A (pt) 2004-11-03
PT1441723E (pt) 2007-07-26
US8088827B2 (en) 2012-01-03
PL368737A1 (en) 2005-04-04
EA007952B1 (ru) 2007-02-27
ZA200402696B (en) 2005-06-29

Similar Documents

Publication Publication Date Title
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
HUP0303363A2 (hu) Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
NO20055649L (no) Substituert dihydrokinazolin med antiviale egenskaper
TW200621765A (en) Substituted phenylaminothiazoles and their use
RS20050070A (en) Use of 1kb kinase inhibitors for the treatment of pain
GB0111186D0 (en) Novel compounds
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
IL161116A0 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
CY1109950T1 (el) Νεα παραγωγα 4,4-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικων) και συνθεσεις που τα περιεχουν
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
MXPA04001205A (es) Compuesto para eliminar y/o mitigar la anhedonia.
UA85187C2 (en) 2-aminobenzoyl derivatives
HK1075390A1 (en) Citalopram for the treatment of elevated blood pressure
WO2004055001A3 (en) Rabeprazole calcium
MXPA02002007A (es) Compuestos de bencimidazol sustituidos con alcoxi, preparaciones farmaceuticas que contienen los mismos, metodos para usarlos.
WO2003014128A3 (de) Tumorhemmende cerverbindungen
SI1441723T1 (sl) Uporaba irbesartana za preprečevanje ali zdravljenje pljučne hipertenzije
UA87851C2 (ru) Производные пирролотриазина, применимые для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
BG105763A (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors